Clinical Trial Update: A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation [Phase 1]

View source ↗

Summary

Phase 1 study evaluating daratumumab in combination with lenalidomide and dexamethasone in Japanese patients with previously untreated multiple myeloma who are …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED